Kestra Medical Technologies (Nasdaq: KMTS) has announced the appointment of Timothy Moran as its new Chief Business Officer (CBO), effective November 3, 2025, marking a key leadership addition as the company advances its commercial expansion and strengthens its position in the cardiac care market.
In his new role, Moran will oversee business strategy, corporate development, payor engagement, reimbursement strategy, contracting, and revenue cycle management for the Kirkland, Washington-based medtech firm. The appointment comes at a crucial time as Kestra accelerates adoption of its Assure Wearable Cardioverter Defibrillator (WCD) and expands its Cardiac Recovery System platform.
“We’re pleased to welcome Tim as our chief business officer,” said Brian Webster, President and CEO of Kestra Medical Technologies. “With extensive expertise in cardiac and heart failure innovation, Tim is well-positioned to join Kestra at this important stage in our commercial ramp. We expect he will help advance our payor and provider partnerships, accelerate adoption of the Cardiac Recovery System platform, and further expand and develop our business strategy.”
Strengthening leadership amid commercial momentum
Kestra, which develops the Assure WCD, has quickly emerged as one of the most closely watched innovators in cardiac protection technology. The Assure system is designed to autonomously detect and deliver therapy for ventricular arrhythmias, providing life-saving defibrillation without requiring bystander intervention. The system also records other clinically significant arrhythmias, offering continuous monitoring that bridges the gap between in-hospital and home-based cardiac care.
Since receiving FDA approval in 2021, the Assure WCD has been positioned as a next-generation alternative to legacy wearable defibrillator systems, with a focus on comfort, patient compliance, and intelligent automation. The device forms part of Kestra’s broader Cardiac Recovery System, a connected platform that supports patients recovering from cardiac arrest or at high risk of sudden cardiac death.
The appointment of Moran adds seasoned leadership to Kestra’s executive team as the company builds on the success of its $202 million initial public offering (IPO) earlier this year. The funding provided Kestra with capital to scale its manufacturing, expand its field teams, and enhance its reimbursement infrastructure to reach more hospitals and cardiac care centers nationwide.
A veteran in cardiac innovation
Timothy Moran brings more than 25 years of leadership experience in the medical device sector, with a strong track record in commercial execution and corporate growth. Most recently, Moran served as President and CEO of Avertix Medical, where he led the commercial introduction of a first-to-market implantable cardiac monitoring system for detecting acute coronary syndrome events — a device designed to provide early warnings of heart attacks and improve patient outcomes.
Prior to that, Moran served as CEO of Motus GI Holdings, a medical device company focused on improving procedural outcomes in gastrointestinal care. His earlier career included senior commercial and operational roles at leading medtech firms, where he oversaw strategy, payer relations, and market expansion initiatives in cardiovascular and diagnostic technologies.
“I’m excited to join Kestra at such a pivotal time in its growth,” Moran said. “Kestra’s commitment to innovation and patient protection aligns perfectly with my passion for building organizations that make a meaningful impact in healthcare. I look forward to collaborating with our payor partners, physicians, and the Kestra team to extend the reach of the Assure WCD and the broader Cardiac Recovery System platform, so that more patients can benefit from proven protection and comprehensive recovery support.”
With Moran’s appointment, Kestra signals a clear intent to deepen its relationships with payors and providers, optimize its commercial infrastructure, and accelerate market adoption of its technologies — reinforcing its mission to redefine cardiac recovery through intelligent, wearable protection.
The appointment of Timothy Moran as Chief Business Officer marks a significant step in Kestra Medical Technologies’long-term strategy to scale its commercial operations and strengthen its foothold in the wearable defibrillator and cardiac recovery market. As the company transitions from early commercialization into sustained growth, Moran’s leadership is expected to play a central role in guiding payer engagement, market access, and strategic partnerships to expand the reach of Kestra’s Assure Wearable Cardioverter Defibrillator (WCD) and its broader Cardiac Recovery System platform.
Post-IPO expansion and strategic growth
Following its successful $202 million initial public offering (IPO) earlier this year, Kestra has moved into an aggressive growth phase, leveraging its capital to expand manufacturing capacity, invest in sales infrastructure, and reinforce its reimbursement capabilities. The company’s post-IPO strategy is centered around a simple but ambitious mission: ensuring that patients at risk of sudden cardiac death (SCD) have greater access to continuous, wearable protection technologies that can autonomously detect and treat life-threatening arrhythmias.
With Moran now overseeing Kestra’s business development and market access functions, the company aims to accelerate its engagement with health systems, cardiology practices, and payor networks across the U.S. Moran’s experience in navigating reimbursement frameworks and establishing payer partnerships will be key as Kestra seeks to streamline patient access and position its technologies for broader insurance coverage and provider adoption.
“Tim’s appointment comes at a defining moment for Kestra,” said Brian Webster, Kestra’s President and CEO. “The company is transitioning from early-stage commercialization into scalable growth, and that requires strategic leadership that understands not just medtech innovation, but how to operationalize it within complex healthcare systems. His track record in both innovation and execution makes him the right leader for this next chapter.”
Redefining the wearable defibrillator market
Kestra’s flagship Assure WCD stands out as a next-generation cardiac protection system designed to deliver autonomous arrhythmia detection and defibrillation without manual intervention. Unlike older-generation devices that rely heavily on patient compliance and manual triggers, Assure integrates real-time analytics, patient monitoring, and automated treatment into a single wearable platform.
The system’s AI-driven arrhythmia detection algorithms and intuitive design provide more reliable and user-friendly protection for patients at risk of ventricular tachycardia or ventricular fibrillation — the most lethal forms of arrhythmia. It also records and transmits clinically significant cardiac data to healthcare providers, supporting continuous care coordination and post-discharge monitoring for patients recovering from cardiac events.
By combining proven efficacy with enhanced comfort and connectivity, Kestra aims to bridge the gap between hospital-grade cardiac protection and home-based patient safety, offering cardiologists a more modern, data-centric approach to cardiac recovery.
Building the future of cardiac recovery
The broader Cardiac Recovery System represents Kestra’s vision for an integrated care ecosystem — one that unites wearable technology, telemedicine, and AI-enabled data analysis to help clinicians monitor, manage, and optimize patient recovery after major cardiac events. The company’s ongoing expansion into this connected ecosystem positions Kestra as more than a device maker — it is evolving into a comprehensive cardiac recovery solutions provider.
Moran’s appointment underscores Kestra’s commitment to executing this long-term vision. With his experience leading high-growth medtech organizations like Avertix Medical and Motus GI, Moran brings both strategic insight and operational discipline. His background in cardiac innovation aligns directly with Kestra’s mission to advance patient protection through intelligent technology and clinical collaboration.
“I’m proud to join a company that is redefining what’s possible in cardiac care,” Moran said. “Kestra has an exceptional product platform and an unwavering focus on patient outcomes. My priority will be to ensure that this technology reaches the patients who need it most — by strengthening payer partnerships, expanding physician relationships, and ensuring that healthcare systems recognize the clinical and economic value of the Assure WCD and Cardiac Recovery System.”
Strengthening Kestra’s market position
Industry analysts have described Kestra as a key emerging competitor in the cardiac wearables space, poised to challenge entrenched players through its advanced automation and patient-centric design. The company’s focus on AI integration, remote monitoring, and clinical workflow compatibility differentiates it in a market that’s becoming increasingly data-driven.
With Moran joining the executive team, Kestra is positioning itself for sustained commercial acceleration, expanded payer coverage, and broader global distribution in the years ahead. His leadership adds a crucial layer of experience in scaling medtech innovations from niche applications to mainstream clinical adoption.
“Kestra is entering its next phase of growth,” Webster said. “With our recent IPO, commercial momentum, and an expanded leadership team, we’re building the infrastructure and partnerships needed to transform the future of cardiac recovery. Tim’s appointment strengthens that foundation.”
As Kestra continues to expand across the U.S. and prepare for future international markets, its focus remains clear: to deliver continuous, autonomous cardiac protection through technology that empowers physicians, supports patients, and advances the standard of cardiac care worldwide.
Powered by Froala Editor